Publications:

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

Annals Of Oncology : Official Journal Of The European Society For Medical Oncology

Kris, M G MG; Camidge, D R DR; Giaccone, G G; Hida, T T; Li, B T BT; O'Connell, J J; Taylor, I I; Zhang, H H; Arcila, M E ME; Goldberg, Z Z; Jänne, P A PA

Publication Date: 2015-07

Variant appearance in text: HER2: 2320A>T

PubMed Link: 25899785

Variant Present in the following documents:

• Main text

View BVdb publication page